pmc-enju-pas Home  

PMC:2664230 / 12528-13416 JSONTXT 18 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T5799 0-4 NN denotes Role
T5800 5-7 IN denotes of
T5801 8-11 NN denotes PKA
T5802 12-14 IN denotes on
T5803 15-26 JJ denotes LPS-induced
T5804 27-38 JJ denotes mononuclear
T5805 39-43 NN denotes cell
T5806 44-49 NN denotes TNF-α
T5807 50-60 NN denotes production
T5808 61-63 TO denotes To
T5809 64-72 VB denotes evaluate
T5810 73-76 DT denotes the
T5811 77-81 NN denotes role
T5812 82-84 IN denotes of
T5813 85-88 NN denotes PKA
T5814 89-91 IN denotes on
T5815 92-97 NN denotes TNF-α
T5816 98-108 NN denotes production
T5817 109-111 IN denotes in
T5818 112-123 JJ denotes mononuclear
T5819 124-129 NN denotes cells
T5820 130-133 CC denotes and
T5821 134-137 PRP-DOLLAR- denotes its
T5822 138-149 NN denotes involvement
T5823 150-152 IN denotes in
T5824 153-156 DT denotes the
T5825 157-168 NN denotes attenuation
T5826 169-171 IN denotes of
T5827 172-183 JJ denotes LPS-induced
T5828 184-189 NN denotes TNF-α
T5829 190-200 NN denotes production
T5830 201-209 VB denotes observed
T5831 210-219 VB denotes following
T5832 220-223 NN denotes PTX
T5833 224-233 NN denotes treatment
T5834 233-234 -COMMA- denotes ,
T5835 235-238 NN denotes H89
T5836 238-239 -COMMA- denotes ,
T5837 240-241 DT denotes a
T5838 242-250 JJ denotes specific
T5839 251-254 NN denotes PKA
T5840 255-264 NN denotes inhibitor
T5841 264-265 -COMMA- denotes ,
T5842 266-269 VB denotes was
T5843 270-278 VB denotes utilized
T5844 280-288 VB denotes Isolated
T5845 289-300 JJ denotes mononuclear
T5846 301-306 NN denotes cells
T5847 307-311 VB denotes were
T5848 312-321 VB denotes incubated
T5849 322-331 VB denotes according
T5850 332-334 TO denotes to
T5851 335-338 DT denotes the
T5852 339-348 NN denotes treatment
T5853 349-355 NN denotes groups
T5854 356-365 VB denotes described
T5855 366-371 RB denotes above
T5856 372-374 IN denotes in
T5857 375-378 DT denotes the
T5858 379-387 NN denotes presence
T5859 388-391 CC denotes and
T5860 392-399 NN denotes absence
T5861 400-402 IN denotes of
T5862 403-415 NN denotes pretreatment
T5863 416-420 IN denotes with
T5864 421-424 NN denotes H89
T5865 425-426 -LRB- denotes (
T5866 426-428 CD denotes 10
T5867 429-431 NN denotes μM
T5868 431-432 -RRB- denotes )
T5869 433-436 IN denotes for
T5870 437-438 CD denotes 1
T5871 439-443 NN denotes hour
T5872 444-446 IN denotes at
T5873 447-451 NN denotes 37ºC
T5874 453-456 DT denotes The
T5875 457-461 NN denotes dose
T5876 462-464 IN denotes of
T5877 465-468 NN denotes H89
T5878 469-472 VB denotes was
T5879 473-479 VB denotes chosen
T5880 480-485 VB denotes based
T5881 486-488 IN denotes on
T5882 489-497 JJ denotes previous
T5883 498-502 NN denotes work
T5884 503-508 WDT denotes which
T5885 509-521 VB denotes demonstrated
T5886 522-530 JJ denotes specific
T5887 531-534 CC denotes and
T5888 535-543 JJ denotes complete
T5889 544-554 NN denotes inhibition
T5890 555-557 IN denotes of
T5891 558-561 NN denotes PKA
T5892 562-564 IN denotes at
T5893 565-569 DT denotes this
T5894 570-586 NN denotes concentration.10
T5895 587-592 IN denotes Since
T5896 593-596 DT denotes the
T5897 597-605 NN denotes activity
T5898 606-608 IN denotes of
T5899 609-613 DT denotes this
T5900 614-623 NN denotes inhibitor
T5901 624-626 VB denotes is
T5902 627-631 CC denotes both
T5903 632-640 JJ denotes specific
T5904 641-644 CC denotes and
T5905 645-655 JJ denotes consistent
T5906 656-658 IN denotes at
T5907 659-663 DT denotes this
T5908 664-673 VB denotes specified
T5909 674-678 NN denotes dose
T5910 678-679 -COMMA- denotes ,
T5911 680-682 PRP denotes we
T5912 683-686 VB denotes did
T5913 687-690 RB denotes not
T5914 691-698 VB denotes include
T5915 699-710 NN denotes experiments
T5916 711-715 IN denotes with
T5917 716-726 JJ denotes additional
T5918 727-730 NN denotes PKA
T5919 731-741 NN denotes inhibitors
T5920 742-746 IN denotes with
T5921 747-751 DT denotes this
T5922 752-755 NN denotes set
T5923 756-758 IN denotes of
T5924 759-770 NN denotes experiments
T5925 772-775 DT denotes The
T5926 776-781 NN denotes TNF-α
T5927 782-795 NN denotes concentration
T5928 796-798 IN denotes in
T5929 799-802 DT denotes the
T5930 803-814 NN denotes supernatant
T5931 815-818 VB denotes was
T5932 819-827 VB denotes measured
T5933 828-842 RB denotes quantitatively
T5934 843-845 IN denotes by
T5935 846-851 NN denotes ELISA
T5936 853-856 DT denotes The
T5937 857-864 NN denotes results
T5938 865-868 VB denotes are
T5939 869-878 VB denotes expressed
T5940 879-881 IN denotes in
T5941 882-887 NN denotes pg/mL
R4831 T5799 T5800 arg1Of Role,of
R4832 T5799 T5802 arg1Of Role,on
R4833 T5801 T5800 arg2Of PKA,of
R4834 T5807 T5802 arg2Of production,on
R4835 T5807 T5803 arg1Of production,LPS-induced
R4836 T5807 T5804 arg1Of production,mononuclear
R4837 T5807 T5805 arg1Of production,cell
R4838 T5807 T5806 arg1Of production,TNF-α
R4839 T5809 T5808 arg1Of evaluate,To
R4840 T5809 T5842 arg1Of evaluate,was
R4841 T5809 T5843 arg2Of evaluate,utilized
R4842 T5811 T5810 arg1Of role,the
R4843 T5811 T5812 arg1Of role,of
R4844 T5811 T5814 arg1Of role,on
R4845 T5811 T5817 arg1Of role,in
R4846 T5811 T5820 arg1Of role,and
R4847 T5813 T5812 arg2Of PKA,of
R4848 T5816 T5814 arg2Of production,on
R4849 T5816 T5815 arg1Of production,TNF-α
R4850 T5819 T5817 arg2Of cells,in
R4851 T5819 T5818 arg1Of cells,mononuclear
R4852 T5820 T5809 arg2Of and,evaluate
R4853 T5822 T5820 arg2Of involvement,and
R4854 T5822 T5821 arg1Of involvement,its
R4855 T5822 T5823 arg1Of involvement,in
R4856 T5825 T5823 arg2Of attenuation,in
R4857 T5825 T5824 arg1Of attenuation,the
R4858 T5825 T5826 arg1Of attenuation,of
R4859 T5829 T5826 arg2Of production,of
R4860 T5829 T5827 arg1Of production,LPS-induced
R4861 T5829 T5828 arg1Of production,TNF-α
R4862 T5829 T5830 arg2Of production,observed
R4863 T5830 T5831 arg1Of observed,following
R4864 T5833 T5831 arg2Of treatment,following
R4865 T5833 T5832 arg1Of treatment,PTX
R4866 T5833 T5834 arg1Of treatment,","
R4867 T5833 T5836 arg1Of treatment,","
R4868 T5835 T5834 arg2Of H89,","
R4869 T5840 T5836 arg2Of inhibitor,","
R4870 T5840 T5837 arg1Of inhibitor,a
R4871 T5840 T5838 arg1Of inhibitor,specific
R4872 T5840 T5839 arg1Of inhibitor,PKA
R4873 T5843 T5841 arg1Of utilized,","
R4874 T5843 T5842 arg2Of utilized,was
R4875 T5846 T5844 arg2Of cells,Isolated
R4876 T5846 T5845 arg1Of cells,mononuclear
R4877 T5846 T5847 arg1Of cells,were
R4878 T5846 T5848 arg2Of cells,incubated
R4879 T5848 T5847 arg2Of incubated,were
R4880 T5848 T5849 arg1Of incubated,according
R4881 T5850 T5849 arg2Of to,according
R4882 T5853 T5850 arg2Of groups,to
R4883 T5853 T5851 arg1Of groups,the
R4884 T5853 T5852 arg1Of groups,treatment
R4885 T5853 T5854 arg2Of groups,described
R4886 T5854 T5855 arg1Of described,above
R4887 T5854 T5856 arg1Of described,in
R4888 T5858 T5859 arg1Of presence,and
R4889 T5859 T5856 arg2Of and,in
R4890 T5859 T5857 arg1Of and,the
R4891 T5859 T5861 arg1Of and,of
R4892 T5859 T5863 arg1Of and,with
R4893 T5860 T5859 arg2Of absence,and
R4894 T5862 T5861 arg2Of pretreatment,of
R4895 T5864 T5863 arg2Of H89,with
R4896 T5864 T5865 arg1Of H89,(
R4897 T5864 T5869 arg1Of H89,for
R4898 T5867 T5865 arg2Of μM,(
R4899 T5867 T5866 arg1Of μM,10
R4900 T5868 T5865 arg3Of ),(
R4901 T5871 T5869 arg2Of hour,for
R4902 T5871 T5870 arg1Of hour,1
R4903 T5871 T5872 arg1Of hour,at
R4904 T5873 T5872 arg2Of 37ºC,at
R4905 T5875 T5874 arg1Of dose,The
R4906 T5875 T5876 arg1Of dose,of
R4907 T5875 T5878 arg1Of dose,was
R4908 T5875 T5879 arg2Of dose,chosen
R4909 T5877 T5876 arg2Of H89,of
R4910 T5879 T5878 arg2Of chosen,was
R4911 T5879 T5880 modOf chosen,based
R4912 T5879 T5881 arg1Of chosen,on
R4913 T5883 T5881 arg2Of work,on
R4914 T5883 T5882 arg1Of work,previous
R4915 T5883 T5884 arg1Of work,which
R4916 T5883 T5885 arg1Of work,demonstrated
R4917 T5886 T5887 arg1Of specific,and
R4918 T5888 T5887 arg2Of complete,and
R4919 T5889 T5885 arg2Of inhibition,demonstrated
R4920 T5889 T5886 arg1Of inhibition,specific
R4921 T5889 T5888 arg1Of inhibition,complete
R4922 T5889 T5890 arg1Of inhibition,of
R4923 T5891 T5890 arg2Of PKA,of
R4924 T5894 T5892 arg2Of concentration.10,at
R4925 T5894 T5893 arg1Of concentration.10,this
R4926 T5894 T5895 arg1Of concentration.10,Since
R4927 T5897 T5896 arg1Of activity,the
R4928 T5897 T5898 arg1Of activity,of
R4929 T5897 T5901 arg1Of activity,is
R4930 T5897 T5903 arg1Of activity,specific
R4931 T5897 T5905 arg1Of activity,consistent
R4932 T5900 T5898 arg2Of inhibitor,of
R4933 T5900 T5899 arg1Of inhibitor,this
R4934 T5901 T5895 arg2Of is,Since
R4935 T5903 T5904 arg1Of specific,and
R4936 T5904 T5901 arg2Of and,is
R4937 T5904 T5902 arg1Of and,both
R4938 T5904 T5906 arg1Of and,at
R4939 T5905 T5904 arg2Of consistent,and
R4940 T5909 T5906 arg2Of dose,at
R4941 T5909 T5907 arg1Of dose,this
R4942 T5909 T5908 arg2Of dose,specified
R4943 T5911 T5912 arg1Of we,did
R4944 T5911 T5914 arg1Of we,include
R4945 T5914 T5885 arg3Of include,demonstrated
R4946 T5914 T5892 arg1Of include,at
R4947 T5914 T5910 arg1Of include,","
R4948 T5914 T5912 arg2Of include,did
R4949 T5914 T5913 arg1Of include,not
R4950 T5915 T5914 arg2Of experiments,include
R4951 T5915 T5916 arg1Of experiments,with
R4952 T5919 T5916 arg2Of inhibitors,with
R4953 T5919 T5917 arg1Of inhibitors,additional
R4954 T5919 T5918 arg1Of inhibitors,PKA
R4955 T5919 T5920 arg1Of inhibitors,with
R4956 T5922 T5920 arg2Of set,with
R4957 T5922 T5921 arg1Of set,this
R4958 T5922 T5923 arg1Of set,of
R4959 T5924 T5923 arg2Of experiments,of
R4960 T5927 T5925 arg1Of concentration,The
R4961 T5927 T5926 arg1Of concentration,TNF-α
R4962 T5927 T5928 arg1Of concentration,in
R4963 T5927 T5931 arg1Of concentration,was
R4964 T5927 T5932 arg2Of concentration,measured
R4965 T5930 T5928 arg2Of supernatant,in
R4966 T5930 T5929 arg1Of supernatant,the
R4967 T5932 T5931 arg2Of measured,was
R4968 T5932 T5933 arg1Of measured,quantitatively
R4969 T5935 T5932 arg1Of ELISA,measured
R4970 T5935 T5934 arg2Of ELISA,by
R4971 T5937 T5936 arg1Of results,The
R4972 T5937 T5938 arg1Of results,are
R4973 T5937 T5939 arg2Of results,expressed
R4974 T5939 T5938 arg2Of expressed,are
R4975 T5939 T5940 arg1Of expressed,in
R4976 T5941 T5940 arg2Of pg/mL,in